Sernova announced today that, as part of a planned leadership succession process, Dr. Philip Toleikis will transition out of the CEO role.
Toleikis spent 13 years leading the Cell Pouch System developer as president and CEO. He remains an executive at the company as the planned transition moves him to chief technology officer (CTO). Additionally, Toleikis will remain CEO during the company’s search period.
Get the full story at our sister site, Drug Delivery Business News.